Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: Implications for in vitro prediction of drug interactions

Drug Metabolism and Disposition

Volumn 34, Issue 12, 2006, Pages 2091-2096

  Karjalainen, Marjo J ^a   Neuvonen, Pertti J ^a   Backman, Janne T ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; FLUVOXAMINE; GLUTATHIONE; MANNITOL; PARACETAMOL; PHENACETIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ROFECOXIB; SUPEROXIDE DISMUTASE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EFFECT; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER MICROSOME; PREDICTION; PRIORITY JOURNAL;

CYTOCHROME P-450 CYP1A2; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; LACTONES; MICROSOMES, LIVER; PHENACETIN; SULFONES;

EID: 33751558274     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.011965     Document Type: Article

References (43)

1. Aoyama T, Korzekwa K, Nagata K, Gillette J, Gelboin HV, and Gonzalez FJ (1990) Estradiol metabolism by complementary deoxyribonucleic acid-expressed human cytochrome P450s. Endocrinology 126:3101-3106.
2. Bachmann K, White D, Jauregui L, Schwartz JI, Agrawal NG, Mazenko R, Larson PJ, and Porras AG (2003) An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe. J Clin Pharmacol 43:1082-1090.
3. Bachmann KA (2006) Inhibition constants, inhibitor concentrations and the prediction of inhibitory drug drug interactions: pitfalls, progress and promise. Curr Drug Metab 7:1-14.
4. Backman JT, Granfors MT, and Neuvonen PJ (2006a) Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 62:451-461.
5. Backman JT, Karjalainen MJ, Neuvonen M, Laitila J, and Neuvonen PJ (2006b) Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. Br J Clin Pharmacol 62:345-357.
6. Berthou F, Flinois JP, Ratanasavanh D, Beaune P, Riche C, and Guillouzo A (1991) Evidence for the involvement of several cytochromes P-450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Dispos 19:561-567.
7. Bertilsson L, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, Lindström L, Rodriguez de la Rubia I, Ramos S, and Benitez J (1994) Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473.
8. Cornelis MC, El-Sohemy A, Kabagambe EK, and Campos H (2006) Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 295:1135-1141.
9. Demotes-Mainard F, Vincon G, Jarry C, and Albin H (1984) [Plasma determination of paracetamol using high performance liquid chromatography. Application to a pharmacokinetic study]. Ann Biol Clin (Paris) 42:9-13.
10. Distlerath LM, Reilly PE, Martin MV, Davis GG, Wilkinson GR, and Guengerich FP (1985) Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260:9057-9067.
11. Faber MS and Fuhr U (2004) Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76:178-184.
12. Facciola G, Hidestrand M, von Bahr C, and Tybring G (2001) Cytochrome P450 isoforms involved in melatonin metabolism in human liver microsomes. Eur J Clin Pharmacol 56:881-888.
13. Fontana E, Dansette PM, and Poli SM (2005) Cytochrome P450 enzymes mechanism based inhibitors: common sub-structures and reactivity. Curr Drug Metab 6:413-454.
14. Ghanbari F, Rowland-Yeo K, Bloomer JC, Clarke SE, Lennard MS, Tucker GT, and Rostami-Hodjegan A (2006) A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr Drug Metab 7:315-334.
15. Granfors MT, Backman JT, Laitila J, and Neuvonen PJ (2004a) Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro. Br J Clin Pharmacol 57:349-353.
16. Granfors MT, Backman JT, Neuvonen M, Ahonen J, and Neuvonen PJ (2004b) Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. Clin Pharmacol Ther 75:331-341.
17. Ha HR, Chen J, Freiburghaus AU, and Follath F (1995) Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 39:321-326.
18. Halpin RA, Porras AG, Geer LA, Davis MR, Cui D, Doss GA, Woolf E, Musson D, Matthews C, Mazenko R, et al. (2002) The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab Dispos 30:684-693.
19. Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290:1116-1125.
20. Kaminsky LS and Zhang ZY (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73:67-74.
21. Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237:3245-3249.
22. Klein K, Saussele T, Toscano C, Blievernicht J, Eichelbaum M, Schwab M, and Zanger UM (2006) Comprehensive analysis of drug metabolizing cytochromes P450 in human liver, in MDO 2006 Book of Abstracts (Vereczkey L ed) pp 127, Budapest, Hungary.
23. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chem Res Toxicol 6:649-656.
24. Lambrecht RW, Sinclair PR, Gorman N, and Sinclair JF (1992) Uroporphyrinogen oxidation catalyzed by reconstituted cytochrome P450IA2. Arch Biochem Biophys 294:504-510.
25. Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, and Rodrigues AD (2003) Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 31:1352-1360.
26. Madden S, Spaldin V, and Park BK (1995) Clinical pharmacokinetics of tacrine. Clin Pharmacokinet 28:449-457.
27. Merck & Co. (2002) VIOXX (rofecoxib tablets and oral suspension), Whitehouse Station, NJ; URL: http://www.merck.com/product/usa/pi_circulars/v/ vioxx/vioxx_pi.pdf. Last accessed: 12 July 2006.
28. Olesen OV and Linnet K (1997) Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 25:740-744.
29. Pufal E, Sykutera M, Rochholz G, Schutz HW, Sliwka K, and Kaatsch HJ (2000) Determination of paracetamol (acetaminophen) in different body fluids and organ samples after solid-phase extraction using HPLC and an immunological method. Fresenius' J Anal Chem 367:596-599.
30. Racha JK, Rettie AE, and Kunze KL (1998) Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry 37:7407-7419.
31. Rasmussen BB, Jeppesen U, Gaist D, and Brøsen K (1997) Griseofulvin and fluvoxamine interactions with the metabolism of theophylline. Ther Drug Monit 19:56-62.
32. Reddy LR and Corey EJ (2005) Facile air oxidation of the conjugate base of rofecoxib (Vioxx(TM)), a possible contributor to chronic human toxicity. Tetrahedron Lett 46:927-929.
33. Renwick AB, Watts PS, Edwards RJ, Barton PT, Guyonnet I, Price RJ, Tredger JM, Pelkonen O, Boobis AR, and Lake BG (2000) Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 28:1202-1209.
34. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, and Wrighton SA (1996) Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658-666.
35. Schwartz JI, Bugianesi KJ, Ebel DL, De Smet M, Haesen R, Larson PJ, Ko A, Verbesselt R, Hunt TL, Lins R, et al. (2000) The effect of rofecoxib on the pharmacodynamics and pharmacokinetics of warfarin. Clin Pharmacol Ther 68:626-636.
36. Silverman RB (1995) Mechanism-based enzyme inactivators. Methods Enzymol 249:240-283.
37. Slaughter D, Takenaga N, Lu P, Assang C, Walsh DJ, Arison BH, Cui D, Halpin RA, Geer LA, Vyas KP, et al. (2003) Metabolism of rofecoxib in vitro using human liver subcellular fractions. Drug Metab Dispos 31:1398-1408.
38. Smith AG, Davies R, Dalton TP, Miller ML, Judah D, Riley J, Gant T, and Nebert DW (2003) Intrinsic hepatic phenotype associated with the Cyp1a2 gene as shown by cDNA expression microarray analysis of the knockout mouse. Environ Health Perspect Toxicogenomics 111:45-51.
39. Tassaneeyakul W, Birkett DJ, Veronese ME, McManus ME, Tukey RH, Quattrochi LC, Gelboin HV, and Miners JO (1993) Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401-407.
40. Wang JS, Backman JT, Taavitsainen P, Neuvonen PJ, and Kivistö KT (2000) Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab Dispos 28:959-965.
41. Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, and Levy RH (2001) Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 70:415-424.
42. Zhang Z, Fasco MJ, Huang Z, Guengerich FP, and Kaminsky LS (1995) Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Dispos 23:1339-1346.
43. Zhang ZY and Kaminsky LS (1995) Characterization of human cytochromes P450 involved in theophylline 8-hydroxylation. Biochem Pharmacol 50:205-211.